

## Farinomalein, a Maleimide-Bearing Compound from the Entomopathogenic Fungus *Paecilomyces farinosus*

Sastia P. Putri,<sup>†</sup> Hiroshi Kinoshita,<sup>†</sup> Fumio Ihara,<sup>‡</sup> Yasuhiro Igarashi,<sup>§</sup> and Takuya Nihira<sup>\*,†,⊥</sup>


International Center for Biotechnology, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan, National Institute of Fruit Tree Science, 2-1 Fujimoto, Tsukuba, Ibaraki 305-8605, Japan, Biotechnology Research Center, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan, and MU-OU Collaborative Research Center for Bioscience and Biotechnology, Faculty of Science, Mahidol University, Rama VI Rd., Bangkok 10400, Thailand

Received May 8, 2009

A new maleimide-bearing compound, farinomalein (**1**), was isolated from the entomopathogenic fungus *Paecilomyces farinosus* HF599. The structure was determined on the basis of spectroscopic analyses and chemical conversion. Compound **1** showed potent activity (5  $\mu\text{g}/\text{disk}$ ) against the plant pathogenic *Phytophthora sojae* P6497.

Entomopathogenic fungi are well known for their ability to produce various bioactive compounds during infection and proliferation in insects<sup>1–3</sup> and, thus, are considered as potential sources of novel bioactive compounds.<sup>4–6</sup> Those belonging to the genus *Paecilomyces* have been the source of a wide range of bioactive metabolites, including the antimalarial and antitumor cyclohexadepsipeptide paecilodepsipeptide A from *P. cinnamomeus*,<sup>7</sup> an antibiotic containing a tetramic acid moiety (paecilosefin from *P. farinosus*<sup>8</sup>), and neurotogenic pyridine alkaloids (farinosones A–C and militarinones A–D from *P. farinosus* and *P. militaris*, respectively<sup>9,10</sup>). During screening for an antioomycete compound against plant pathogenic oomycetes, the EtOAc extract of *P. farinosus* HF599 showed strong inhibitory activity against *Phytophthora sojae*.<sup>11</sup> Detailed investigation of the fungal extract led to the identification of the new maleimide compound 3-(3-isopropyl-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoic acid, which we have named farinomalein (**1**). Farinomalein (**1**) showed potent inhibition of the plant pathogen *Phytophthora sojae*, with an MIC value of 5  $\mu\text{g}/\text{disk}$ , whereas the MIC of the antifungal agent amphotericin B is 10  $\mu\text{g}/\text{disk}$ . We herein describe the isolation, structure elucidation, and biological activity of farinomalein (**1**).

The producing strain was isolated from a lepidopteran larval cadaver collected on Mt. Tsukuba, Ibaraki, Japan. This fungus was identified as *Paecilomyces farinosus* on the basis of morphological criteria. Compound **1**, the major metabolite of *P. farinosus* HF599, was not detected in the extract of another active isolate of *P. farinosus*, HF656 (data not shown).



Farinomalein (**1**) was obtained as a white powder. High-resolution ESITOFMS revealed an  $[M + Na]^+$  at  $m/z$  234.0710, corresponding to the molecular formula  $C_{10}H_{13}NO_4$  (calcd for  $C_{10}H_{13}NO_4Na$ , 234.0737). The <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic data (Table 1) were in agreement with the assigned molecular formula. The <sup>13</sup>C NMR spectrum of **1** showed 10 signals, indicating five

aliphatic carbons (one of them bonded to nitrogen), two carbons in the olefinic region, and two carbonyl carbons. The <sup>1</sup>H NMR spectrum in combination with the HSQC spectrum revealed proton signals for two methyl, two methylene, an aliphatic methine, and an olefinic methine group. The COSY spectrum demonstrated two fragments: H-6–H-5–H-7 and H-8–H-9 (Figure 1). HMBC correlations from H-3 to C-1, C-2, and C-4 and from H-5 to C-1, C-2, and C-3 established the maleimide core and the substitution of an isopropyl group at C-2. Furthermore, the HMBC correlation from H-8 to C-1 and C-4 suggested bonding of C-8 to the maleimide nitrogen. HMBC correlations from H-8 and H-9 to C-10, in consideration of the molecular formula, led to the suggestion of the presence of a carboxylic acid at the terminus. The location of the nitrogen was confirmed by the observation of <sup>1</sup>H–<sup>15</sup>N long-range couplings between the protons H-3, H-8, and H-9 and the nitrogen ( $\delta$  147.1). For verification of the presence of carboxylic acid, **1** was treated with MeI and DBU to afford a methylated derivative (**2**). In the <sup>1</sup>H NMR of **2**, a singlet methyl was observed at  $\delta$  3.64, and it showed HMBC correlation to C-10, thereby confirming the location of carboxylic acid. The UV absorption at 223 nm is typical for a maleimide ring.<sup>12</sup> High-resolution ESITOFMS of **2** revealed an  $[M + Na]^+$  at  $m/z$  248.0910 corresponding to the molecular formula  $C_{11}H_{15}NO_4$  (calcd for  $C_{11}H_{15}NO_4Na$ , 248.0893). The IR spectrum was consistent with the presence of the symmetric (1778  $\text{cm}^{-1}$ ) and asymmetric (1717  $\text{cm}^{-1}$ ) maleimide C=O stretches and the maleimide symmetric C–N–C stretch ( $\sim$ 1405  $\text{cm}^{-1}$ ),<sup>13</sup> as well as the presence of OH (3113  $\text{cm}^{-1}$ ) and carbonyl (1702  $\text{cm}^{-1}$ ) groups, thereby confirming the structure of **1** as indicated.

Reports of natural compounds bearing maleimide rings are very limited. Examples include showdomycin from *Streptomyces showdoensis*, pencolide from *Penicillium multicolor*, and turrapubesin from the twigs and leaves of *Turraea pubescens*.<sup>14–16</sup> The isopropyl moiety attached at C-2 on the maleimide ring is, to our best knowledge, a unique structural feature that has not been reported previously in natural compounds.

Recently, maleimides such as *N*-methylmaleimide, *N*-ethylmaleimide, and phenylmaleimide PM-20 have attracted the interest of many researchers due to their cytotoxicity toward tumor cell lines through the inhibition of human topoisomerase II<sup>17</sup> or the inhibition of Cdc25A.<sup>18</sup> These facts suggested that, in addition to its potent antioomycete activity, farinomalein (**1**) could also possess other biological functions, such as cytotoxicity toward tumor cell lines.

### Experimental Section

**General Experimental Procedures.** UV spectra were recorded on a Hitachi U-3210 spectrophotometer. IR spectra were recorded on a

\* To whom correspondence should be addressed. Tel: +81-6-6879-7452. Fax: +81-6-6879-7454. E-mail: nihira@icb.osaka-u.ac.jp.

<sup>†</sup> Osaka University.

<sup>‡</sup> National Institute of Fruit Tree Science.


<sup>§</sup> Toyama Prefectural University.

<sup>⊥</sup> Mahidol University.

**Table 1.** NMR Spectroscopic Data for Farinomalein (1) and Its Methyl Ester (2) in CD<sub>3</sub>OD

position	farinomalein (1)			farinomalein-Me (2)		
	$\delta_{\text{H}}$ (mult, $J$ in Hz) <sup>b</sup>	$\delta_{\text{C}}$ <sup>c</sup>	HMBC <sup>b</sup>	$\delta_{\text{H}}$	$\delta_{\text{C}}$	HMBC
1		172.6 <sup>a</sup>			170.8 <sup>a</sup>	
2		157.3			156.0	
3	6.37 (d, 1.6)	126.0	1, 2, 4, 5, 6, (7)	6.37 (d, 1.6)	126.0	
4		172.3 <sup>a</sup>			170.8 <sup>a</sup>	
5	2.80 (dh, 1.6, 6.9)	27.2	1, 2, 3, 6, (7)	2.80 (dh, 1.6, 6.9)	27.2	
6, 7	1.21 (d, 6.9)	21.3	2, 5, 6, 7	1.21 (d, 6.9)	21.3	2, 5, 6, 7
8	3.74 (t, 7.2)	34.9	1, 4, 9, 10	3.75 (t, 7.0)	34.9	1, 9
9	2.58 (t, 7.2)	34.0	8, 10	2.60 (t, 7.0)	34.0	8, 10
10		175.0			172.0	
11				3.64 (s)	52.5	10

<sup>a</sup> Exchangeable. <sup>b</sup> Recorded at 500 MHz. <sup>c</sup> Recorded at 100 MHz.

**Figure 1.** COSY, HMBC, and <sup>15</sup>N HMBC correlations of 1.

Perkin-Elmer Spectrum 100 spectrophotometer. NMR spectra were obtained on a Bruker AV400 M or on a Bruker AVANCE 500 spectrometer. The <sup>1</sup>H and <sup>13</sup>C chemical shifts were referenced to the solvent signals ( $\delta_{\text{H}}$  3.3 and  $\delta_{\text{C}}$  49.1 in CD<sub>3</sub>OD). The <sup>15</sup>N chemical shift was referenced to the external signal of formamide. HRESITOFMS were recorded on a Bruker microTOF focus spectrometer. HPLC analyses were carried out on an Agilent HP1100 system using a Cosmosil 5C18-AR-II column (4.6 × 100 mm; Nacalai Tesque Inc.). The solvent used to dissolve 1 was methanol unless stated otherwise.

**Microorganism.** The entomopathogenic fungus *Paecilomyces farinosus* HF599 was isolated from a Lepidopteran larval cadaver collected on Mt. Tsukuba, Ibaraki, Japan. Fungal conidia that developed on the surface of the dead larva were transferred to SMY and incubated at 25 °C for several days.<sup>20</sup> After the conidia had developed on SMY slants, the strain was kept at -30 °C as a stock culture. The isolated strain was identified as *P. farinosus* according to its morphology by one of the authors (F.I.). The fungus is deposited at the culture collection of National Institute of Fruit Tree Science.

**Fermentation.** All chemicals, media, and reagents were purchased from Wako, Japan, unless stated otherwise. The seed culture was prepared as follows. The mycelium of *P. farinosus* HF599 grown on a slant culture was inoculated into 100 mL flasks each containing 30 mL of the seed medium, SMY [maltose 4%, yeast extract 1%, peptone 1%], and cultivated at 25 °C for 3 days. The seed culture (5 mL) was transferred into 500 mL baffled flasks containing 250 mL of the production medium [SMY supplemented with Diaion HP-20 (Mitsubishi Chemical Co., Japan) 1%], which were cultured at 25 °C for 21 days under static conditions.

**Extraction and Isolation.** The mixture of 21-day-old mycelium and fermentation broth of strain HF599 (250 mL × 8 flasks) was extracted with ethyl acetate (without prior saturation with water, 250 mL per flask) by stirring for 1 h. The mixture was separated by filtration using Miracloth (Calbiochem, San Diego, CA), and the filtrate was again extracted with 1 L of ethyl acetate. The organic layer was separated from the aqueous layer in an extraction funnel and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. Evaporation of the solvent provided approximately 1 g of extract per 2 L of culture. A portion of the crude extract (500 mg) was subjected to reversed-phase column chromatography using a Sep-Pak Vac 35 cm<sup>3</sup> (10 g) C<sub>18</sub> cartridge (Waters, Millford, MA) with a step gradient of CH<sub>3</sub>CN-H<sub>2</sub>O (0:1, 1:9, 2:8, and 1:0 v/v). Final purification was conducted by reversed-phase HPLC on a Shiseido Capcell-Pak C<sub>18</sub> column (5  $\mu$ m; 250 × 10 mm i.d.) with 20% CH<sub>3</sub>CN + 0.1% TFA to yield 1 (45.6 mg/g extract).

**Farinomalein (1):** white powder; UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ) 223 (4.27), 288 (2.26); IR 3113, 1778, 1717, 1702, 1405; <sup>1</sup>H, <sup>13</sup>C NMR, HMBC, see Table 1; HRESITOFMS  $m/z$  [M + Na]<sup>+</sup> 234.0710 (calcd for C<sub>10</sub>H<sub>13</sub>NO<sub>4</sub> Na 234.0737).

**Methylation of Farinomalein (1).** A solution of 1 (500  $\mu$ g), methyl iodide (few drops), and 1,8-diazabicyclo[5.4.0]-7-undecene (trace amount) in acetone (50  $\mu$ L) and CH<sub>3</sub>CN (50  $\mu$ L) was heated at 50 °C

for 1 h in darkness. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was successively washed with diluted aqueous HCl and brine and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The organic layer was concentrated *in vacuo* to obtain methyl ester 2. The obtained residue (200  $\mu$ g) containing the methyl ester as the major constituent (>90% purity as shown by HPLC) was directly used for analysis.

**Methyl Ester of Farinomalein (2):** <sup>1</sup>H, <sup>13</sup>C NMR,<sup>22</sup> HMBC, see Table 1; HRESITOFMS  $m/z$  [M + Na]<sup>+</sup> 248.0910 (calcd for C<sub>11</sub>H<sub>15</sub>NO<sub>4</sub>Na, 248.0893).

**Antioomycete Assay.** *In vitro* antioomycete activity was determined by the disk diffusion susceptibility test following the method described previously<sup>21</sup> with several modifications. Loaded paper disks (1, 5, 10, 50, 100  $\mu$ g/disk) (8.0 mm; Advantec, Japan) were air-dried on a clean bench for 30 min prior to placing on the Petri dish. The minimal inhibitory concentration was defined as the lowest concentration resulting in inhibition of mycelial growth after 48–96 h of incubation at 25 °C. The indicator strain, *P. sojae* P6497, was grown at 25 °C on V8-juice agar [vegetable juice without NaCl (COOP, Japan) 20% v/v, CaCO<sub>3</sub> 0.2%, agar 1.8%]. The reference compound used in this assay, amphotericin B, was dissolved in DMSO. No growth inhibition was observed in the control disks (loaded with 50  $\mu$ L of MeOH or DMSO).

**Acknowledgment.** We thank Dr. Y. Sakihama of Hokkaido University for providing the *Phytophthora sojae* P6497 and Ms. M. Azumi and Mr. T. Fukuda for technical assistance during the NMR and mass spectrometric analyses. This study was supported in part by a scholarship from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan to S.P. and by a grant for a “Research Project in the Field of Biotechnology” from MEXT, the National Research Council of Thailand, and the National Science and Technology Development Agency of Thailand to T.N.

**Supporting Information Available:** <sup>1</sup>H NMR, <sup>13</sup>C NMR, and HMBC spectra of farinomalein (1) and <sup>1</sup>H NMR, HSQC, and HMBC spectra of its methyl ester (2). This information is available free of charge via the Internet at <http://pubs.acs.org>.

## References and Notes

- (1) Jan Scholte, E.; Knols, B. G.; Samson, R. A.; Takken, W. *J. Insect Sci.* **2004**, *4*, 1–24.
- (2) Thomas, M.; Read, A. *Nat. Rev. Microbiol.* **2007**, *5*, 377–383.
- (3) Zimmermann, G. *Biocontrol Sci. Technol.* **2007**, *17*, 553–596.
- (4) Azumi, M.; Ishidoh, K.; Kinoshita, H.; Nihira, T.; Ihara, F.; Fujita, T.; Igarashi, Y. *J. Nat. Prod.* **2008**, *71*, 278–280.
- (5) Lee, S. Y.; Kinoshita, H.; Ihara, F.; Igarashi, Y.; Nihira, T. *J. Biosci. Bioeng.* **2008**, *105*, 476–480.
- (6) Isaka, M.; Kittakoop, P.; Kirtikara, K.; Hywel-Jones, N. L.; Thebtaranonth, Y. *Acc. Chem. Res.* **2005**, *38*, 813–823.
- (7) Isaka, M.; Palasarn, S.; Lapanun, S.; Sriklung, K. *J. Nat. Prod.* **2007**, *70*, 675–678.
- (8) Lang, G.; Blunt, J. W.; Cummings, N. J.; Cole, A. L.; Munro, M. H. *J. Nat. Prod.* **2005**, *68*, 810–811.
- (9) Cheng, Y.; Schneider, B.; Riese, U.; Schubert, B.; Li, Z.; Hamburger, M. *J. Nat. Prod.* **2004**, *67*, 1854–1858.
- (10) Schmidt, K.; Gunther, W.; Stoyanova, S.; Schubert, B.; Li, Z. *Org. Lett.* **2002**, *89*, 197–199.
- (11) Putri, S. P.; Kinoshita, H.; Kitani, S.; Ihara, F.; Igarashi, Y.; Nihira, T. *Mycologia*, submitted.

- (12) Hargreaves, M.; Pritchard, J.; Dave, H. *Chem. Rev.* **1970**, *70*, 439–469.
- (13) Shen, G.; Anand, M. F.; Levicky, R. *Nucleic Acids Res.* **2004**, *32*, 5973–5980.
- (14) Nakagawa, Y.; Kano, H.; Tsukuda, Y.; Koyama, H. *Tetrahedron Lett.* **1967**, *42*, 4105–4109.
- (15) Birkinshaw, J.; Kalyanpur, M.; Stickings, C. *Biochem. J.* **1963**, *86*, 237–243.
- (16) Wang, X.; Yin, S.; Fan, C.; Wang, F.; Lin, L.; Ding, J.; Yue, J. *Org. Lett.* **2006**, *8*, 3845–3848.
- (17) Jensen, L. H.; Renodon-Corniere, A.; Wessel, I.; Langer, S. W.; Sokilde, B.; Carstensen, E. V. *Mol. Pharmacol.* **2002**, *61*, 1235–1243.
- (18) Filho, V.; Pinheiro, T.; Nunes, R.; Yunes, R.; Bella Cruz, A.; Moretto, A. *Farmaco* **1994**, *49*, 675–677.
- (19) Kar, S.; Wang, M.; Yao, W.; Michejda, C. J.; Carr, B. I. *Mol. Cancer Ther.* **2006**, *5*, 1511–1519.
- (20) Ihara, F.; Yaginuma, K.; Kobayashi, N.; Mishiuro, K.; Sato, T. *Appl. Entomol. Zool.* **2001**, *38*, 495–500.
- (21) Deora, A.; Hashidoko, Y.; Islam, M.; Tahara, S. *Eur. J. Plant Pathol.* **2005**, *112*, 311–322.
- (22) Due to the limited amount of the sample, <sup>13</sup>C signals were not fully detected and the chemical shifts were determined indirectly by analyzing HSQC and HMBC spectra.

NP9002806